Novel targeted therapies for non-small cell lung cancer.
Targeted therapies will advance the treatment of NSCLC as we improve our understanding of the underlying biology of NSCLC and enhance our ability to clinically target the optimal therapy to an individual's cancer. Ongoing translational research including tissue arrays, genomic, and proteomic studies will help to identify clinically useful biomarkers that will allow further classification of NSCLC and may allow accurate prediction of response to specific chemotherapeutic regimens. Advances in targeted therapy in NSCLC are already yielding exciting results, and promises to become an increasingly important adjunct to surgical management of NSCLC.
Smith
Philip W
PW
University of Virginia, School of Medicine, P.O. Box 800679, Lee Street, Charlottesville, VA 22908-0679, USA.
Denlinger
Chadrick E
CE
Jones
David R
DR
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000627:therapeutic use; D047488:Retinoid X Receptors / Q000819:agonists; D018631:ras Proteins / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D052246:Cyclooxygenase 2 Inhibitors; D056572:Histone Deacetylase Inhibitors; D011480:Protease Inhibitors; D047488:Retinoid X Receptors; D066246:ErbB Receptors; D018631:ras Proteins